Alicia T. Widge - Concepedia

Author

Alicia T. Widge

National Institute of Allergy and Infectious Diseases ORCID

Also Known As

Alicia T Widge, Alicia T. Widge, Alicia Toeruna Widge, Alicia Widge, Cristina Carter, Wei Shi

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Emory University Leidos (United States)Frederick National Laboratory for Cancer Research

About

Alicia T. Widge is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	554
2	Public Health	1	1	10
3	Allergy	1	1	10
4	Family Medicine	1	1	10
5	Health Behavior	1	1	10

Alicia T. Widge

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Evan J. Anderson, Nadine Rouphael, Alicia T. Widge, New England Journal of Medicine	2020	1.6K
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, New England Journal of Medicine	2020	1.1K
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants Lingshu Wang, Tongqing Zhou, Yi Zhang, Science	2021	212
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization Nicole A. Doria‐Rose, Xiaoying Shen, Stephen D. Schmidt, VaccinationVaccine SafetyVaccine DevelopmentMedicineVaccine Surveillance	2021	129
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults Alicia T. Widge, Amelia R. Hofstetter, Katherine V. Houser, Science Translational Medicine	2023	88
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial Joseph P. Casazza, Evan M. Cale, Sandeep Narpala, Nature Medicine VaccinationNeutralizing AntibodyHuman RetrovirusImmunologyAntiviral Therapy	2022	82
An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans Sarah F. Andrews, Lauren Y. Cominsky, Geoffrey D. Shimberg, Science Translational Medicine	2023	72
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial Tracy J. Ruckwardt, Kaitlyn M. Morabito, Emily Phung, The Lancet Respiratory Medicine VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	62
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter, The Lancet VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetImmunology	2023	62

Page 1